| |
CRP-positive patients
|
CRP-negative patients
|
|---|
| |
Baseline value
|
Adjusted mean changes (95% CI)
|
P-value
|
Baseline value
|
Adjusted mean changes (95% CI)
|
P-value
|
|---|
| | |
<4 years
|
≥4 years
| | |
<4 years
|
≥4 years
| |
|---|
| | |
n = 30
|
n = 15
| | |
n = 26
|
n = 37
| |
|---|
|
BASDAI
|
5.4
|
3.3 (2.7, 4.0)
|
2.4 (1.5, 3.3)
|
0.11
|
5.5
|
3 (2.3, 3.7)
|
1.3 (0.7, 1.9)
|
0.001
|
|
BASFI
|
4.2
|
2.4 (1.8, 3.0)
|
1.8 (0.9, 2.7)
|
0.23
|
4.5
|
2.4 (1.8, 3.1)
|
0.9 (0.4, 1.5)
|
0.001
|
|
BASMI
|
1.5
|
0.1 (−0.3, 0.4)
|
0.4 (−0.1, 0.9)
|
0.30
|
2.0
|
0.5 (0, 1)
|
−0.3 (−0.6, 0.1)
|
0.01
|
|
ASDAS
|
3.6
|
1.9 (1.6, 2.2)
|
1.5 (1.1, 1.9)
|
0.07
|
2.8
|
1.3 (1, 1.6)
|
0.6 (0.3, 0.8)
|
0.001
|
|
CRP*
|
13.8
|
2.7 (2.2, 3.3)
|
2.1 (1.5, 3)
|
0.20
|
3.6
|
1.2 (1, 1.5)
|
1.2 (1, 1.4)
|
0.86
|
|
MRI SIJ
|
6.6
|
4.6 (3.6, 5.7)
|
3.5 (2, 4.9)
|
0.19
|
3.8
|
2.5 (1.8, 3.2)
|
2.5 (1.9, 3.1)
|
0.96
|
- *Log-transformed CRP results were back-transformed; P-value <0.05 was taken to indicate statistically significant differences between two groups; adjusted mean changes from baseline under treatment with etanercept or adalimumab (95% CI). Outcome differences were adjusted for baseline status (see Methods). BASDAI, Bath ankylosing spondylitis disease activity index; BASFI, Bath ankylosing spondylitis functional index; BASMI, Bath ankylosing spondylitis metrology index; ASDAS, ankylosing spondylitis disease activity score; CRP, C-reactive protein in mg/l; MRI, magnetic resonance imaging; SIJ, sacroiliac joint.
